INCY
$82.33
Incyte
($.04)
(.05%)
INCY
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  $0.56
Revenue:  $692.37 Mil
Tuesday
Aug 3
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when INCY reports earnings?
Beat
Meet
Miss

Where is INCY's stock price going from here?
Up
Flat
Down
Stock chart of INCY
Analysts
Summary of analysts' recommendations for INCY
Score
Grade
Pivots
Resistance
$87.47
$85.36
$83.86

$81.75

Support
$80.25
$78.14
$76.64
Tweet
Growth
Description
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.
Peers
Alexion PharmaceuticalsExact SciencesCharles River Laboratories InternationalExelixisCoherus BiosciencesLuminex